VEGFA and ocular hypertension: When grouped by the type of anti-VEGF agents, the incidence of ocular hypertension caused by the combination treatment of triamcinolone and bevacizumab was significantly higher than that of bevacizumab monotherapy (RR 11.200, 95% CI 2.687 to 46.685, 95% PI 0.349 to 223.314; I2 = 0%, Tau2 = 0) (Table 3).